Apollomics (APLM) Assets (2022 - 2025)

Apollomics (APLM) posted quarterly Assets of $6.7 million for Q4 2025, down 90.59% quarter-over-quarter from $71.4 million in Q2 2023.

Apollomics (APLM) Assets (2022 - 2025) Analysis & Trends

Apollomics (APLM) has reported Assets for 3 consecutive years, with $6.7 million the latest figure, recorded in Q4 2025.

In Q4 2025, Assets changed N/A year-over-year to $6.7 million; the TTM figure through Dec 2025 stood at $6.7 million (changed N/A YoY), while the FY2025 annual figure was $6.7 million, changed N/A from the prior year.
Assets slipped to $6.7 million in Q4 2025 per APLM's latest filing, from $71.4 million in the prior quarter.
Across five years, Assets topped out at $76.5 million in Q4 2022 and bottomed at $6.7 million in Q4 2025.
Historically, Assets has averaged $51.5 million across 3 years, with a median of $71.4 million in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	10.03 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	5.56 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	2.10 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.82 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	25.60 Bn
10	Apollomics	34.08 Mn	30.81 Mn	-	6.71 Mn

Download Data